T a family of closely related proteins with multiple biological activities on many cell types.' These proteins were initially characterized by their ability to induce transient anchorage independence of some cell lines.2 More recently, it has become apparent that TGF-@ plays a complex role as a mediator of inflammation, tissue repair, and angiogenesis and also as a regulator of cell pr~liferation.~ Although TGF-@ can induce proliferation of some cell types, its ability to inhibit proliferation of both tumor and normal cells is well known. This is especially true of epithelial cells, but inhibition of the growth of cells of mesenchymal origin has also been reported.' On hematopoietic cells, TGF-@ inhibits growth factor-stimulated proliferation and colony formation of normal bone marrow (BM) cell^.^*^ In contrast to the large number of studies reporting effects of TGF-@ on cell proliferation, much less is known about the ability of TGF-@ to affect terminal differentiation. TGF-@ can induce terminal differentiation of bronchial epithelial cells, however. 6 We investigated whether TCF-@ plays a role in regulation of proliferation and differentiation of two human leukemic cell lines: the promyelocytic cell line HL60 and the monoblastic cell line U937. These cell lines retain their immature morphology and cytochemistry in vitro and can be terminally differentiated after treatment with various agents.'.' TGF-@ acts in synergy with tumor necrosis factor-a (TNF-a) to inhibit proliferation and to induce differentiation of both cell lines.
MATERIALS AND METHODS
Bovine TGF-81 and TGF-82 were purified to homogeneity as described elsewhere.' A polyclonal rabbit anti-TGF-8 antisera was purchased from R&D System (Minneapolis, MN). Human recombinant TNF-a (specific activity 2 x IO' U/mg) was from Genzyme (Boston, MA). Human recombinant interferon-y IFN--, (specific activity 2.5 x lo7 U/mg) was a gift from Biogen (Cambridge, MA), and human recombinant IFN-aA (specific activity 2 x IO8 U/mg) was a gift from Dr P. Sorter of HoffmannLaRoche (Nutley, NJ). All trans-retinoic acid (RA, Sigma Chemical, St Louis, MO) was dissolved in dimethylsulfoxide (DMSO) and then diluted at least 10,000-fold into the culture medium so that the final concentration of DMSO was never higher than 0.01%. Nitroblue tetrazolium (NBT) and phorbol myristate acetate (PMA) were obtained from Sigma.
The HL60 cell line (passage 29) was provided by Dr T. Breitman (National Institutes of Health, Bethesda, MD). HL60 and U937 cells were cultured in polystyrene tissue culture flasks in RPMI 1640 medium supplemented with 10% heatinactivated fetal calf serum (FCS), glutamine, penicillin, and streptomycin for HL60 cells and with 10% heat-inactivated FCS, glutamine, nonessential aminoacids, HEPES, and gentamicin for U937 cells. For HL60 cells, passages 35 through 60 were used. Experiments were always initiated with exponentially growing cells. For thymidine uptake experiments, 2 x lo4 cells/well were incubated in 200 pL complete medium in 96-well plates for 4 days at 37°C in a humidified atmosphere of 5% C 0 2 with the various treatments, as indicated. During the last 12 hours of incubation, 1 pCi of 'H-thymidine (specific activity 40 to 60 Ci/mmol, Amersham, Arlington Heights, IL) was added to each well. Cultures were harvested on glass-fiber filters, and 'H-thymidine uptake was measured. . The specific activity of the I2'1-TGF-j3 varied between 100 and 140 pCi/pg depending on the preparation. At the end of the incubation, the cell-bound ligand was separated from the unbound ligand by centrifugation at 4OC through a 2:l (vol/vol) mixture of dibutyl phthalate and dinonyl phthalate (EM Science, Cherry Hill, NJ) as previously described.', The cell pellet was counted in a y-counter. Nonspecific binding was calculated from the plateau of the competition curve and was subtracted from total binding. Specific binding data were analyzed by the method of Scatchard."
For affinity labeling, HL60 and U937 cells were seeded in tissue culture flasks at the same cell density used for differentiation experiments and incubated with various treatments for 24 or 72 hours as indicated. After two washes in binding buffer (RPMI 1640 medium containing 1 mg/mL BSA, 2 mmol/L glutamine, and 0.1% sodium azide), the cell pellet was resuspended in 1 mL binding buffer and acidified using CO, (g). After pelleting, cells were resuspended in binding buffer and aliquoted (5 x IO6 cells/l mL) into siliconized Eppendorf tubes. To determine nonspecific binding, samples were preincubated for 10 minutes at 4OC with or without a 50-fold excess of unlabeled TGF-j31. Samples were then incubated with 1 x lo6 cpm '*'I-TGF-p for 30 minutes at 4OC with constant rotation. Cells were then washed once in cross-linking buffer (PBS, 10 mmol/L MgCI,, pH 8.3) and incubated for 30 minutes at 4°C with constant rotation in 1 mL cross-linking buffer containing 100 pg disuccinimidylsuberate (Pierce Chemical, Rockford, IL). After two washes, cells were incubated for 30 minutes at 4OC in lysis buffer (20 mmol/L Tris-C1 pH 7.4, 50 mmol/L NaC1,0.5% NP-40,0.5% sodium deoxycholate, 4 mmol/L iodoacetic acid, 5 mmol/L sodium pyrophosphate, 5 mmol/L sodium fluoride, 1 mmol/L phenylmethylsulfonylfluoride, PMSF). The protein content of each lysate was determined with a commerEvaluation ofcell differentiation.
Binding assays.
Afinity labeling with 'z5Z-TGF-p.
cially available kit (BioRad Protein Assay, BioRad Laboratories, Richmond, CA), and equal amounts of protein in each sample were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) under reducing conditions (5% 2-mercaptoethanol) with 7% to 15% gradient gels, followed by autoradiography.
RESULTS
Effect of TGF-/3 on proliferation and differentiation of HL60 and U937 cells. Incubation of HL60 cells for 4 days with varying concentrations of TGF-PI or TGF-@2 alone had little or no effect on cell proliferation, as measured by 'H-thymidine uptake (Fig 1) . We then treated HL60 cells with combinations of TGF-8 and other inducers of differentiation, such as TNF-a, IFN-a, IFN-7, and RA. The concentrations of these factors were chosen according to published When HL60 cells were incubated with TGF-01 in combination with TNF-a, a synergistic antiproliferative effect was observed (Fig 1) . Addition of an anti-TGF-/3 antisera neutralized the effect of TGF-/31 (data not shown). TGF-/32 also synergized with TNF-a in inhibiting proliferation of HL60 cells, although it was somewhat less effective than TGF-P1 (Fig 1) . Similar results were obtained when cell proliferation was measured by counting cells in a hemacytometer (data not shown).
Because combinations of TNF-a and TGF-/3 strongly inhibited the growth of HL60 cells, we examined the effect of treatment with combinations of TGF-P and TNF-a on differentiation of HL60 cells. Similar to what occurred with cell proliferation, treatment with TGF-P1 alone did not induce significant differentiation (Fig 2) . As previously reported, treatment with 5 ng/mL (100 U/mL) TNF-a alone induced monocytic differentiation of a small percentage of the cells.'4 Addition of TGF-P1 resulted in a dosedependent increase in the percentage of cells differentiated toward the monocytic lineage, as evaluated by the percentage of cells that reduced NBT and expressed ANAE, a marker of monocytic lineage (Fig 2) , and that showed monocytic morphology (data not shown).
For better definition of the role of TGF-/3 in promotion of monocytic differentiation, we then tested whether TGF-P was also able to synergize with other known inducers of monocytic differentiation of HL60 cells. (Table 1) showed that TGF-81 did not potentiate differentiation induced by IFN-a or IFN-y alone or in combination with RA. In contrast, TGF-Pl enhanced monocytic differentiation of cells treated either with TNF-a alone or with a combination of RA and TNF-a. To investigate whether the synergy between TGF-8 and TNF-a in inducing monocytic differentiation could be generalized to other cell lines, we tested the effect of combinations of TGF-P1 and TNF-a on proliferation and differentiation of the monoblastic cell line U937. TGF-81 alone inhibited cell proliferation, with maximal inhibition of approximately 70% (Fig 3) , in agreement with previous observation^.^ In addition, TGF-P acted synergistically with TNF-a to inhibit proliferation, as shown by the isobologram (Fig 3) . Similar results were obtained when cell proliferation was evaluated by counting cells in a hemacytometer (data not shown). Similar to the effect observed on HL60 cells, treatment of U937 cells with TGF-P1 and TNF-a resulted in synergistic induction of monocytic differentiation, evaluated by the percentage of cells that reduced NBT (Fig 4) and that expressed mature monocytic morphology (data not shown).
Increase in TGF-0 receptor expression on HL60 and U937 cells after treatment with TNF-a. To investigate a possible mechanism of the synergy between TNF-a and TGF-P, we examined the effect of treatment with TNF-a on TGF-/3 receptor expression and the effect of treatment with TGF-(3 on TNF-a receptor expression on HL60 and U937 cells.
Affinity labeling of many cell types with '251-TGF-/3 typically shows the presence of three cross-linked complexes with molecular weights (mol wt) of 65,85, and >200 Kd. '9,20 Examination of TGF-P receptor expression by affinity labeling of HL60 and U937 cells showed that both cell lines expressed detectable levels of TGF-P binding proteins (Fig  5 ) . Untreated U937 cells appeared to have much higher levels of TGF-/3 receptors than untreated HL60 cells, how- Treatment of HL60 and U937 cells with TNF-a for 24 hours induced an increase in TGF-(3 specific binding of approximately four-to fivefold and twofold, respectively (data not shown). However, owing to high nonspecific binding we could not generate reliable values for the number of binding sites and the dissociation constant by Scatchard analysis of TGF-P binding data for these cells.
We also tested the effect of the treatment with other inducers of monocytic differentiation on expression of TGF-(3 receptors on HL60 cells. As shown in Fig 6, Table 2 , treatment of HL60 and U937 cells with TGF-P had no significant effect on TNF-a receptor expression on either cell line.
DISCUSSION
We report that TGF-(3 potentiates the antiproliferative effect of TNF-a on both HL60 and U937 cell lines and strongly synergizes with TNF-a in inducing monocytic differentiation of these cell lines. To our knowledge, this is the first report that describes an effect of TGF-(3 on differentiation of myeloid leukemic cell lines, suggesting that TGF-(3 may be one of the signals that plays a role in monocytic differentiation of hematopoietic cells.
Both TGF-(31 and TGF-/32 synergized with TNF-a in inhibiting proliferation of HL60 cells. TGF-/31 appeared to be more potent than TGF-/32, however. Although this could result from some loss of biological activity of TGF-(32 during purification, it may reflect an actual difference in biological activity of these two molecules on hematopoietic cells or, under the conditions used, to be specific for the presence of
Our data suggest that, depending on the inducing stimuli, different biochemical and cellular events play a role in the commitment and subsequent differentiation of HL60 cells toward the monocytic lineage. The different effect of TGF-B TNF-U. in the presence of TNF-a compared with either IFN-u or IFN-y could represent a useful experimental system to dissect the biochemical events involved in monocytic differentiation of leukemic and possibly normal hematopoietic cells.
With regard to the mechanism of the synergy between TNF-a and TGF-8 in inducing monocytic differentiation of HL60 and U937 cells, treatment of both cell lines with There was also good correlation between the ability of a particular cytokine to increase TGF-/3 receptor expression and its ability to synergize with TGF-(3 in inducing monocytic differentiation of HL60 cells; TNF-a, but not IFN-7, with or without RA, both significantly increased TGF-/3 receptor expression and synergized with TGF-/3 in inducing monocytic differentiation. These results suggest that the observed synergy between TNF-a and TGF-(3 may result, at least in part, from the TNF-a-induced increase in TGF-(3 receptor expression. Whether postreceptor events also play a role in the synergy between TNF-a and TGF-/3 in inducing monocytic differentiation has not been determined.
We observed that U937 cells, which are already committed to the monocytic lineage, express higher levels of TGF-/3 receptors than the less differentiated HL60 cells and that the level of TGF-/3 receptor expression correlates with the differing sensitivity of these two cell lines to treatment with TGF-/3 alone. Moreover, peripheral blood monocytes have been reported to have detectable levels of TGF-(3 receptor^.'^ However, there does not appear to be a generalized increase in TGF-(3 receptor expression during monocytic differentiation because treatment of HL60 cells with a combination of IFN-7 and RA, which very effectively induced monocytic differentiation, did not significantly increase expression of TGF-/3 binding proteins a t the time point examined.
Finally, with regard to the role of TGF-/3 in regulation of hematopoiesis, TGF-/3 has been reported to inhibit formation of colonies from immature precursor^.^.^ Based on these previous observations and our present data, we hypothesize that TGF-(3 may play a bifunctional role in hematopoiesis both by inhibiting proliferation of immature precursors and by promoting differentiation of late precursors committed to the monocytic lineage. In vivo, TGF-/3 may protect immature precursors from the effect of cell cycle-active drugs and concurrently induce differentiation of leukemic cells, and therefore have therapeutic application.
